Does Rallies show Form 4 insider transactions for BEAT?

Yes. Rallies tracks BEAT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BEAT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BEAT. It does not provide personalized investment advice.

BEAT (Heartbeam, Inc. Common Stock) Stock Analysis - Insider Trades

Heartbeam, Inc. Common Stock (BEAT) is a publicly traded Healthcare sector company. As of May 21, 2026, BEAT trades at $0.92 with a market cap of $53.25M and a P/E ratio of -1.51. BEAT moved +1.75% today. Year to date, BEAT is -66.51%; over the trailing twelve months it is -44.72%. Its 52-week range spans $0.54 to $4.00. Analyst consensus is strong buy with an average price target of $4.50. Rallies surfaces BEAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BEAT stock inside the company?

Recent BEAT insider activity includes Ferrari Richard bought 57.50K, Cruickshank Tim bought 31.25K, Elfrink Willem bought 187.50K, JAFF MICHAEL R bought 31.25K, and Vajdic Branislav bought 31.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BEAT Key Metrics

Key financial metrics for BEAT
Metric	Value
Price	$0.92
Market Cap	$53.25M
P/E Ratio	-1.51
EPS	$-0.62
Dividend Yield	0.00%
52-Week High	$4.00
52-Week Low	$0.54
Volume	4.48K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-21.02M
Gross Margin	0.00%

Recent BEAT Insider Trades

Ferrari Richard bought 57.50K (~$46.00K) on Apr 16, 2026.
Cruickshank Tim bought 31.25K (~$25.00K) on Apr 16, 2026.
Elfrink Willem bought 187.50K (~$150.00K) on Apr 16, 2026.
JAFF MICHAEL R bought 31.25K (~$25.00K) on Apr 16, 2026.
Vajdic Branislav bought 31.25K (~$25.00K) on Apr 16, 2026.

Latest BEAT News

HeartBeam Advances U.S. Commercial Launch, Raises $11.5M, Cuts Q1 Loss to $4.7M — May 14, 2026
HeartBeam to deploy leadless AI ECG platform in Atelier Health practices — May 7, 2026
HeartBeam Launches Next-Gen ECG System to Address 919,000 Annual U.S. Cardiac Deaths — May 6, 2026
HeartBeam Partners with Mount Sinai to Validate AI-Based 12-Lead ECG Algorithms — Apr 24, 2026
HeartBeam Raises $10M from 12.5M-Share Offering to Fuel ECG Technology Commercialization — Apr 17, 2026

BEAT Analyst Consensus

6 analysts cover BEAT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.50.

Common questions about BEAT

Who is trading BEAT stock inside the company?: Recent BEAT insider activity includes Ferrari Richard bought 57.50K, Cruickshank Tim bought 31.25K, Elfrink Willem bought 187.50K, JAFF MICHAEL R bought 31.25K, and Vajdic Branislav bought 31.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BEAT?: Yes. Rallies tracks BEAT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BEAT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BEAT. It does not provide personalized investment advice.